Committed to the Future of Antibiotics

13 September 2016

Da Volterra is Presenting at the Targeting the Microbiome Conference 2016

Da Volterra is pleased to share that our Chief Scientific (...)

5 July 2016

Da Volterra Presented Highly Convincing Results of Pre-clinical Studies at ASM 2016 : DAV132 Prevents CDI

Professor Antoine Andremont, founder of Da Volterra, presented (...)

16 June - 20 June 2016

Da Volterra at ASM Microbe 2016

We are happy to announce our participation at ASM Microbe on (...)

Who we are

Da Volterra:
Committed to the Future of Antibiotics

Da Volterra is a biotechnology company developing a portfolio of unique products in the antibacterial field, with a specific focus on antibiotic resistance.

Our most advanced product is DAV132, developed to prevent the disruption of the intestinal microbiota and prevent Clostridium difficile infections associated with antibiotic use. Discover DAV132 in the video below:

DAV132 has already undergone three phase I clinical trials. It has been developed using in-house expertise on resistant gut microbiomes and proprietary drug delivery technologies. Learn more >

500,000 Americans infected
by Clostridium difficile
each year

Learn more >


Developpeur PHP Drupal